Jeff Bousfield, CEO of Advanced Genomics, welcomes the increased NHS funding announced in the UK Government’s Budget yesterday, which can further accelerate technology adoption from innovative UK companies to reduce costs and cut waiting lists in our health system.
Jeff commented: “For the majority in the UK, our NHS is the foundation of our quality of life, and we welcome the increased investment announcement by the Government.
“We would be delighted to see that investment increasingly used to research, test and adopt pioneering innovations by UK companies which can transform patient care at a fraction of the cost of current methods.
“GALEAS™ Bladder, our at-home test for early-stage bladder cancer, removes the need for patients to visit overburdened NHS Trusts for a painful and embarrassing procedure, providing the same quality of cancer detection in the comfort of their own homes at a fraction of the cost.
“This is just one of the many innovative technologies created by UK companies within our world-leading healthcare ecosystem that can continue to support our health system and improve patient care for years to come.”
Advanced Genomics is a UK-headquartered group of companies advancing non-invasive healthcare through the power of genetics, creating innovative cancer testing that transforms patient care and builds towards our mission of making early cancer detection, diagnosis and management available to all.
The group has offices in the UK and Taiwan and is best known for creating the world’s first saliva-based PCR COVID test, co-delivering the NHS’s largest hereditary cancer study, and most recently creating the world’s first standard-of-care equivalent genetic bladder cancer test.
